The article was removed by YellowAssessmentMonkey 00:30, 12 May 2009 [1].
This article has a number of issues.
There was a 25 percent decrease in the incidence of prostate cancer in men assigned to finasteride (803 of 4368 [18.4 percent] versus 1147 of 4692 [24.4 percent] with placebo). The magnitude of the risk reduction did not differ according to PSA level, age, race/ethnicity, or family history of prostate cancer.
Despite the overall decrease in cases of prostate cancer among those receiving finasteride, both the absolute number and proportion of more aggressive prostate cancers (ie, Gleason score ≥7) were significantly higher in the finasteride group (280 of 757 [37 percent] versus 237 of the 1068 [22 percent] in the placebo group). However, 98 percent of tumors were T1 or T2 in both groups, and only five men in each group died of prostate cancer.
Treatment was well tolerated. Finasteride increased sexual dysfunction only slightly by six months after randomization compared to placebo, and its impact diminished over time [12]. Urinary symptoms were less common in the finasteride group (frequency or urgency, 12.9 versus 15.6 percent with placebo, urinary retention, 4.2 versus 6.3 percent, need for transurethral resection of the prostate, 1.0 versus 1.9 percent) [11].
-- Doc James ( talk · contribs · email) 13:48, 13 April 2009 (UTC) reply
The article was removed by YellowAssessmentMonkey 00:30, 12 May 2009 [1].
This article has a number of issues.
There was a 25 percent decrease in the incidence of prostate cancer in men assigned to finasteride (803 of 4368 [18.4 percent] versus 1147 of 4692 [24.4 percent] with placebo). The magnitude of the risk reduction did not differ according to PSA level, age, race/ethnicity, or family history of prostate cancer.
Despite the overall decrease in cases of prostate cancer among those receiving finasteride, both the absolute number and proportion of more aggressive prostate cancers (ie, Gleason score ≥7) were significantly higher in the finasteride group (280 of 757 [37 percent] versus 237 of the 1068 [22 percent] in the placebo group). However, 98 percent of tumors were T1 or T2 in both groups, and only five men in each group died of prostate cancer.
Treatment was well tolerated. Finasteride increased sexual dysfunction only slightly by six months after randomization compared to placebo, and its impact diminished over time [12]. Urinary symptoms were less common in the finasteride group (frequency or urgency, 12.9 versus 15.6 percent with placebo, urinary retention, 4.2 versus 6.3 percent, need for transurethral resection of the prostate, 1.0 versus 1.9 percent) [11].
-- Doc James ( talk · contribs · email) 13:48, 13 April 2009 (UTC) reply